Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

Martin Farlow, Ann Hake, J. Messina, R. Hartman, J. Veach, R. Anand

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment. Objective: To evaluate retrospectively whether rate of disease progression during placebo treatment affects response to subsequent rivastigmine tartrate therapy for patients with mild to moderately severe AD. Design: A 26-week, open-label extension study following a 26-week, double-blind, randomized, placebo-controlled trial. Settings: Outpatient research centers at 22 sites in the United States. Patients: We studied 187 of 235 patients originally randomized to receive placebo treatment in the doubleblind phase of the trial who continued with open-label (rivastigmine) extension therapy. Intervention: Placebo treatment for 26 weeks followed by rivastigmine treatment, 2 to 12 mg/d, for 26 weeks. Main Outcome Measures: Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), Progressive Deterioration Scale, Mini-Mental State Examination, and Global Deterioration Scale scores. Results: Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. Slowly progressive patients responded with a mean 1.03-point improvement in the week 26 (ie, start of open-label rivastigmine treatment) ADAS-Cog score at 12 weeks of rivastigmine treatment (week 38 of treatment; P = .02 vs week 26). However, more rapidly progressive patients had a significantly larger mean 4.97-point improvement from the week 26 ADAS-Cog score at 12 weeks (with respect to week 26 of treatment and slowly progressive patient scores, P<.001 for both). Thus, a more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy. This relation also was observed with the other 3 outcome measures and was still apparent when accounting for disease severity. Conclusions: Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment. Patients with more rapidly progressive disease might be particularly likely to benefit from rivastigmine therapy.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalArchives of Neurology
Volume58
Issue number3
StatePublished - 2001

Fingerprint

Rivastigmine
Disease Progression
Alzheimer Disease
Therapeutics
Placebos
Progression
Alzheimer's Disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. / Farlow, Martin; Hake, Ann; Messina, J.; Hartman, R.; Veach, J.; Anand, R.

In: Archives of Neurology, Vol. 58, No. 3, 2001, p. 417-422.

Research output: Contribution to journalArticle

@article{5793005705dc4f08ab07270da4599dc2,
title = "Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression",
abstract = "Background: Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment. Objective: To evaluate retrospectively whether rate of disease progression during placebo treatment affects response to subsequent rivastigmine tartrate therapy for patients with mild to moderately severe AD. Design: A 26-week, open-label extension study following a 26-week, double-blind, randomized, placebo-controlled trial. Settings: Outpatient research centers at 22 sites in the United States. Patients: We studied 187 of 235 patients originally randomized to receive placebo treatment in the doubleblind phase of the trial who continued with open-label (rivastigmine) extension therapy. Intervention: Placebo treatment for 26 weeks followed by rivastigmine treatment, 2 to 12 mg/d, for 26 weeks. Main Outcome Measures: Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), Progressive Deterioration Scale, Mini-Mental State Examination, and Global Deterioration Scale scores. Results: Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. Slowly progressive patients responded with a mean 1.03-point improvement in the week 26 (ie, start of open-label rivastigmine treatment) ADAS-Cog score at 12 weeks of rivastigmine treatment (week 38 of treatment; P = .02 vs week 26). However, more rapidly progressive patients had a significantly larger mean 4.97-point improvement from the week 26 ADAS-Cog score at 12 weeks (with respect to week 26 of treatment and slowly progressive patient scores, P<.001 for both). Thus, a more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy. This relation also was observed with the other 3 outcome measures and was still apparent when accounting for disease severity. Conclusions: Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment. Patients with more rapidly progressive disease might be particularly likely to benefit from rivastigmine therapy.",
author = "Martin Farlow and Ann Hake and J. Messina and R. Hartman and J. Veach and R. Anand",
year = "2001",
language = "English",
volume = "58",
pages = "417--422",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

AU - Farlow, Martin

AU - Hake, Ann

AU - Messina, J.

AU - Hartman, R.

AU - Veach, J.

AU - Anand, R.

PY - 2001

Y1 - 2001

N2 - Background: Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment. Objective: To evaluate retrospectively whether rate of disease progression during placebo treatment affects response to subsequent rivastigmine tartrate therapy for patients with mild to moderately severe AD. Design: A 26-week, open-label extension study following a 26-week, double-blind, randomized, placebo-controlled trial. Settings: Outpatient research centers at 22 sites in the United States. Patients: We studied 187 of 235 patients originally randomized to receive placebo treatment in the doubleblind phase of the trial who continued with open-label (rivastigmine) extension therapy. Intervention: Placebo treatment for 26 weeks followed by rivastigmine treatment, 2 to 12 mg/d, for 26 weeks. Main Outcome Measures: Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), Progressive Deterioration Scale, Mini-Mental State Examination, and Global Deterioration Scale scores. Results: Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. Slowly progressive patients responded with a mean 1.03-point improvement in the week 26 (ie, start of open-label rivastigmine treatment) ADAS-Cog score at 12 weeks of rivastigmine treatment (week 38 of treatment; P = .02 vs week 26). However, more rapidly progressive patients had a significantly larger mean 4.97-point improvement from the week 26 ADAS-Cog score at 12 weeks (with respect to week 26 of treatment and slowly progressive patient scores, P<.001 for both). Thus, a more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy. This relation also was observed with the other 3 outcome measures and was still apparent when accounting for disease severity. Conclusions: Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment. Patients with more rapidly progressive disease might be particularly likely to benefit from rivastigmine therapy.

AB - Background: Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment. Objective: To evaluate retrospectively whether rate of disease progression during placebo treatment affects response to subsequent rivastigmine tartrate therapy for patients with mild to moderately severe AD. Design: A 26-week, open-label extension study following a 26-week, double-blind, randomized, placebo-controlled trial. Settings: Outpatient research centers at 22 sites in the United States. Patients: We studied 187 of 235 patients originally randomized to receive placebo treatment in the doubleblind phase of the trial who continued with open-label (rivastigmine) extension therapy. Intervention: Placebo treatment for 26 weeks followed by rivastigmine treatment, 2 to 12 mg/d, for 26 weeks. Main Outcome Measures: Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), Progressive Deterioration Scale, Mini-Mental State Examination, and Global Deterioration Scale scores. Results: Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. Slowly progressive patients responded with a mean 1.03-point improvement in the week 26 (ie, start of open-label rivastigmine treatment) ADAS-Cog score at 12 weeks of rivastigmine treatment (week 38 of treatment; P = .02 vs week 26). However, more rapidly progressive patients had a significantly larger mean 4.97-point improvement from the week 26 ADAS-Cog score at 12 weeks (with respect to week 26 of treatment and slowly progressive patient scores, P<.001 for both). Thus, a more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy. This relation also was observed with the other 3 outcome measures and was still apparent when accounting for disease severity. Conclusions: Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment. Patients with more rapidly progressive disease might be particularly likely to benefit from rivastigmine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035106966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035106966&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 417

EP - 422

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -